BLC
GMAB icon

Brown, Lisle/Cummings’s Genmab GMAB Stock Holding History

Brown, Lisle/Cummings’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.07K Buy
+77
New +$2.31K ﹤0.01% 814

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Brown, Lisle/Cummings's GMAB Position: Q1 2026 in Review

Brown, Lisle/Cummings opened a new position in Genmab (GMAB) in Q1 2026: 77 shares worth $2.07K. The stake represents ﹤0.01% of the portfolio and ranks #814 among its holdings.

275 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Brown, Lisle/Cummings held 77 shares of Genmab worth $2.07K as of Q1 2026.
  • Genmab was a new Brown, Lisle/Cummings position in Q1 2026.
  • Genmab made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #814 holding.
  • 275 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.